A Phase III, multicentre, randomized, double-blind clinical study, investigating the efficacy and safety of repeated 12-week courses of daily 5mg or 10mg doses of PGL4001 for the long-term management of symptomatic uterine fibroids
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Ulipristal (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms PEARLIV
- Sponsors PregLem
- 21 Nov 2016 According to an Allergan media release, based on the data from this and other study the Health Canada approved Fibristal (ulipristal acetate, 5 mg) for the intermittent treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age.
- 15 Oct 2015 Results published in the Fertility and Sterility
- 09 Oct 2015 According to a Gedeon Richter media release, results from this trial were presented at the European Society of Gynaecological Endoscopy (ESGE) Congress.